Latest Remote magnetic navigation Stories
New technology maps the electronic signals of the heart 3 dimensionally Researchers at the Intermountain Heart Institute at Intermountain Medical Center have developed a new 3-D technology that for the first time allows cardiologists the ability to see the precise source of atrial fibrillation in the heart – a breakthrough for a condition that affects nearly three million Americans. This new technology that maps the electronic signals of the heart three dimensionally significantly...
Presentations Review Findings from Nearly 1,000 Clinical Cases Performed in Germany to Date MARLBOROUGH, Mass., April 10, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced today that cardiologists throughout Germany gathered to discuss clinical experiences with the HeartLight System and its role in the treatment of advanced AF. The featured event was held on April 3, in conjunction...
MARLBOROUGH, Mass., Jan. 14, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces the U.S. pivotal trial evaluating the safety and efficacy of the HeartLight system is approximately half enrolled. The study, initiated in 2012, is on track to complete enrollment this year. HeartLight is the first catheter ablation system to incorporate an endoscope for direct visualization of the...
MARLBOROUGH, Mass., Jan. 10, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that as of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. The company will be hosting an expert symposium to review the clinical application of HeartLight and key observations made during the first 1,000 cases, which will be held the evening of...
MARLBOROUGH, Mass., Sept. 6, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new data showing pulmonary vein isolation (PVI) with its technology leads to a 99% acute success rate and up to an 82% chronic success rate at 12 months follow-up. In addition, the research indicates the HeartLight laser balloon technology resulted in improved long-term outcomes after a single...
